[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Stoke Therapeutics Inc (STOK)

Stoke Therapeutics Inc (STOK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,048,093
  • Shares Outstanding, K 62,271
  • Annual Sales, $ 184,420 K
  • Annual Income, $ -6,890 K
  • EBIT $ -21 M
  • EBITDA $ -20 M
  • 60-Month Beta 1.20
  • Price/Sales 11.07
  • Price/Cash Flow N/A
  • Price/Book 5.31

Options Overview Details

View History
  • Implied Volatility 84.63% (+13.40%)
  • Historical Volatility 36.05%
  • IV Percentile 24%
  • IV Rank 28.42%
  • IV High 151.84% on 05/30/25
  • IV Low 57.95% on 05/20/25
  • Expected Move (DTE 4) 3.08 (9.43%)
  • Put/Call Vol Ratio 1.92
  • Today's Volume 35
  • Volume Avg (30-Day) 75
  • Put/Call OI Ratio 2.12
  • Today's Open Interest 4,150
  • Open Int (30-Day) 4,315
  • Expected Range 29.56 to 35.72

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.79
  • Number of Estimates 4
  • High Estimate $-0.55
  • Low Estimate $-0.94
  • Prior Year $-0.40
  • Growth Rate Est. (year over year) -97.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
31.28 +4.35%
on 05/08/26
37.35 -12.61%
on 04/17/26
-1.69 (-4.92%)
since 04/10/26
3-Month
29.86 +9.31%
on 03/19/26
40.22 -18.85%
on 03/10/26
+0.42 (+1.30%)
since 02/11/26
52-Week
8.70 +275.03%
on 05/14/25
40.22 -18.85%
on 03/10/26
+23.28 (+248.72%)
since 05/09/25

Most Recent Stories

More News
Stoke Therapeutics Q1 Earnings Call Highlights

Stoke Therapeutics (NASDAQ:STOK) said its lead investigational therapy zorevunersen continued to show durable seizure reductions and improvements in measures of cognition and behavior in four-year open-label...

STOK : 32.64 (-0.76%)
Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates

– New 4-year longitudinal data from the Phase 1/2a open-label extension (OLE) studies provide additional support for the disease-modifying potential of zorevunersen, an investigational medicine for the...

STOK : 32.64 (-0.76%)
BIIB : 197.95 (+2.33%)
Stoke Therapeutics' Mounting Losses May Actually Validate Its Platform Better Than a Profit Would

Barchart Research What to Expect from STOK Earnings STOK Generated May 6, 2026 Current Price $33.28 EPS Estimate $$-0.80 Consensus Rating Strong Buy Average Move 6.37% Stoke Therapeutics' Mounting Losses...

STOK : 32.64 (-0.76%)
Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial Updates

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...

STOK : 32.64 (-0.76%)
BIIB : 197.95 (+2.33%)
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...

STOK : 32.64 (-0.76%)
Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...

STOK : 32.64 (-0.76%)
BIIB : 197.95 (+2.33%)
Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...

STOK : 32.64 (-0.76%)
BIIB : 197.95 (+2.33%)
Stoke Therapeutics Faces Mounting Losses as Earnings Loom

STOK : 32.64 (-0.76%)
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...

STOK : 32.64 (-0.76%)
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome

–Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with this rare, devastating genetic neurodevelopmental disease– ...

STOK : 32.64 (-0.76%)
BIIB : 197.95 (+2.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Stoke Therapeutics Inc. is a biopharmaceutical company. It develops antisense oligonucleotide medicines to treat genetic diseases. The company's product candidate consists of STK-001 which is to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics Inc. is based in Bedford,...

See More

Key Turning Points

3rd Resistance Point 36.28
2nd Resistance Point 35.31
1st Resistance Point 33.98
Last Price 32.64
1st Support Level 31.68
2nd Support Level 30.71
3rd Support Level 29.38

See More

52-Week High 40.22
Last Price 32.64
Fibonacci 61.8% 28.18
Fibonacci 50% 24.46
Fibonacci 38.2% 20.74
52-Week Low 8.70

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.